報價延遲最少15分鐘:2025/07/17 16:43 EDT
盤後時段
|
||||
|
20.05 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.05
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.05/-2.20
|
|
企業價值
222.67M
|
| 資產負債 |
|
每股賬面淨值
2.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
20.22M
|
|
每股收益
2.41
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 16:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets. |
